



# JFL LIFE SCIENCES LIMITED

**April 08, 2025**

To  
The General Manager (Listing)  
**National Stock Exchange of India Limited**  
5<sup>th</sup> Floor, Exchange Plaza,  
Plot No. c/1, G Block, Bandra-Kurla Complex, Bandra (East)  
Mumbai-400051

**Respected Sir(s),**

**SUB: - OUTCOME OF BOARD OF DIRECTORS MEETING**

**NSE SYMBOL: JFLIFE; ISIN: INE0LA901015**

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on March 27, 2025, at the Registered Office of the company have

1. Considered and approved Unaudited Financial Results for nine months ended December 31, 2024 along with Limited Review Report.
2. The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, appointed Ms. Amita Pragada as an Additional Independent Director with effect from April 08, 2025.

Details as required pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 with respect to the appointment of Independent Director are given as per **Annexure A**.

The Meeting Commenced at 02:30 PM and Concluded at 3:10 PM.

This is for your kind information and records.

Thanking You.

Yours Truly,

**For JFL LIFE SCIENCES LIMITED**

**SMIRAL ASHWINKUMAR PATEL**  
**Managing Director**  
**DIN: 00769486**

## Annexure A

SR. NO.	Particulars	Details
1	Reason for change viz. Appointment, re-appointment, resignation, removal, death or otherwise.	Appointment as an Additional Independent Director
2	Date of appointment/ re-appointment/cessation (as applicable) and term of appointment / re-appointment.	08-04-2025 Term-Till the ensuing General Meeting
3	Brief profile (in case of appointment)	Amita Pragada is an associate member of the Institute of Company Secretaries of India having good experience in corporate laws of 7 years. She is also a Bachelor of Commerce and Bachelor of Law from Saurashtra University and Gujarat University respectively.
4	Disclosure of relationships between Directors (in case of appointment of a Director)	<b>Not Applicable</b>

**JFL Life Sciences Limited**

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTTELITE, AHMEDABAD 380015  
 Tele No. +91-93772 95575, Email Id :- info@jfllifesciences.com, www.jfllifesciences.com

**UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 31st DECEMBER, 2024**

(Rs. In Lakhs)

SR.NO.	PARTICULARS.	Quarters Ended on			Nine Months Ended on		Financial Year
		31.12.2024 (UNAUDITED)	30.09.2024 (UNAUDITED)	31.12.2023 (UNAUDITED)	31.12.2024 (UNAUDITED)	31.12.2023 (UNAUDITED)	ended on 31.03.2024 (AUDITED)
	<b>INCOMES</b>						
I	Revenue from Operations	2,124.83	3,951.10	559.87	7,030.42	2,484.29	4,654.79
II	Other Income	1.04	0.04	41.60	1.48	49.69	52.37
	<b>Total Income (I + II)</b>	<b>2,125.87</b>	<b>3,951.14</b>	<b>601.47</b>	<b>7,031.90</b>	<b>2,533.98</b>	<b>4,707.16</b>
III	<b>EXPENSES</b>						
IV	Cost of materials consumed	1,910.15	3,586.91	466.52	6,192.05	1,840.89	3,823.22
(a)	Purchase of Stock in Trade.	-	-	-	-	-	-
(b)	Changes of Inventories of Finished Goods,	-23.21	33.48	(134.34)	(90.71)	64.53	62.46
	Work in Progress, Work in Trade.	-	-	-	-	-	-
(c)	Employee benefits expense	30.69	36.88	118.88	126.99	162.63	201.31
(d)	Finance Cost	20.14	27.22	36.96	73.66	55.43	82.61
(e)	Depreciation and Amortisation Expenses	15.93	23.90	12.64	63.74	33.57	44.27
(f)	Other Expenses	72.99	53.21	67.39	121.62	135.41	113.30
	<b>TOTAL EXPENSES (IV (a to g))</b>	<b>2,026.70</b>	<b>3,761.60</b>	<b>568.04</b>	<b>6,487.36</b>	<b>2,292.46</b>	<b>4,327.17</b>
V	<b>Profit/(Loss) before Exceptional Items and Tax. (III-IV)</b>	<b>99.17</b>	<b>189.55</b>	<b>33.43</b>	<b>544.54</b>	<b>241.53</b>	<b>379.99</b>
VI	Exceptional Items. & Extraordinary Item	-	-	-	-	-	-
VII	<b>Profit/ (Loss) Before Tax. (V-VI)</b>	<b>99.17</b>	<b>189.55</b>	<b>33.43</b>	<b>544.54</b>	<b>241.53</b>	<b>379.99</b>
VIII	<b>TAX EXPENSES.</b>						
(a)	Current Tax.	24.26	46.44	7	133.41	50.72	79.52
(b)	Deferred Tax.	0.69	1.27	-3	3.65	-19.32	(30.31)
	<b>Total Tax Expenses.</b>	<b>24.95</b>	<b>47.71</b>	<b>4.35</b>	<b>137.06</b>	<b>31.40</b>	<b>49.21</b>
IX	<b>NET PROFIT / (LOSS) FOR THE PERIOD</b>	<b>74.22</b>	<b>141.84</b>	<b>29.09</b>	<b>407.48</b>	<b>210.13</b>	<b>330.79</b>
X	Paid up Equity Share Capital (Amount in lacs)	3,299.53	1,099.84	1,099.84	3,299.53	1,099.84	1,099.84
	Rs. 10 Face value per share) (Refer Note 7)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XI	Other Equity Capital (Reserve & Surplus)	-	-	-	-	-	-
XII	Earning Per Share (In Rupees)						
(i)	Basic.	0.22	0.43	0.09	1.23	0.64	1.00
(ii)	Diluted.	0.22	0.43	0.09	1.23	0.64	1.00

**NOTES:**

- These financial result were reviewed by the Board of Directors and thereafter have been approved by the board of directors at its meeting held on Friday, Apr 04, 2025. The Statutory Auditors have carried out limited review of the financial result for the Nine months ended on Dec 31, 2024.
- The statement has been prepared in accordance with the recognition and measurement principles laid down in the Relevant Accounting Standard prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and the terms of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended.
- As per MCA Notification dated 16th Feb 2015, Companies whose shares are listed on the SME Exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the Compulsory requirement of adoption of Ind AS for the preparation of Financial Results,
- Company has only one reportable segment - Pharmaceuticals Manufacturing
- Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.
- The financial results for the Three month ended December 31, 2024 are balancing figures between Audited results for the Half Year ended September 30, 2024 and the published year to date figure upto Nine months ended December 31, 2024.
- Company has issued Bonus Shares during the period in the ratio of 1:2 (2 Shares against every 1 Share held). Allotment for the same has already been made, However, in-principle approval is still awaited.

For JFL Life Sciences Limited

Smiral A. Patel

Director

DIN : 00769486

Dated : 08th Apr, 2025

Place : Ahmedabad



**Independent Auditor's Review Report on the Quarter Ended December 31, 2024, Unaudited Financial Results of JFL LIFE SCIENCES LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To**

**The Board of Directors**

**JFL LIFE SCIENCES LIMITED**

309, Satyam Mall, Opp. Saman Complex,

Nr. Vishweshwar Mahadev Mandir, Settelite,

Ahmedabad, Gujrat, India, 380015

1. We have reviewed the accompanying statement of unaudited financial results of **JFL Life Sciences Limited** (the 'Company') for the quarter ended December 31, 2024 and year to date from April 01, 2024 December 31, 2024 for the Nine month ended on that date (the "Statement"). This statement is prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We draw attention to the note number 7 of unaudited financial results, which describes pendency of in-principal approval on issuance of Bonus Shares during the period in the ratio of 1:2 (2 Shares against every 1 Share held). Company have allotted the Bonus shares during the period in the ratio of 1:2. Our opinion is not modified in respect of this matter.

# Doshi Doshi & Co

Chartered Accountants

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doshi Doshi & Co,**  
Chartered Accountants

**Firm Registration No.: 153683W**

CHINTAN Digitally signed by  
CHINTAN  
RAJESHBHAI RAJESHBHAI DOSHI  
Date: 2025.04.08  
11:41:28 +05'30'

**Chintan R. Doshi**

Partner

Membership No.:158931

**UDIN: 25158931BMIFTP2362**

Place: Ahmedabad

Date: April 08, 2025

☎ 9167 404 303

✉ chintan@ddco.in

🌐 www.ddco.in

📍 **Ahmedabad Branch**

C 908, Stratum @ Venus Ground,  
NR Jhansi Ki Rani Statue,  
Nehrunagar, Ahmedabad - 380015

📍 **Mumbai Branch**

119, Plot No. 7, Near F M Banquets,  
Udyog Nagar, Goregaon West,  
Mumbai - 400104.